155 related articles for article (PubMed ID: 23223398)
1. Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Jones GM; Twilla JD; Hoit DA; Arthur AS
J Neurointerv Surg; 2013 Sep; 5(5):e38. PubMed ID: 23223398
[TBL] [Abstract][Full Text] [Related]
2. Prevention of stent thrombosis with reduced dose of prasugrel in two patients undergoing treatment of cerebral aneurysms with pipeline embolisation devices.
Jones GM; Twilla JD; Hoit DA; Arthur AS
BMJ Case Rep; 2012 Oct; 2012():. PubMed ID: 23104636
[TBL] [Abstract][Full Text] [Related]
3. A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel) study.
Trenk D; Stone GW; Gawaz M; Kastrati A; Angiolillo DJ; Müller U; Richardt G; Jakubowski JA; Neumann FJ
J Am Coll Cardiol; 2012 Jun; 59(24):2159-64. PubMed ID: 22520250
[TBL] [Abstract][Full Text] [Related]
4. Use of prasugrel in a patient with clopidogrel hypersensitivity.
Peppard SR; Held-Godgluck BM; Beddingfield R
Ann Pharmacother; 2011 Oct; 45(10):e54. PubMed ID: 21896923
[TBL] [Abstract][Full Text] [Related]
5. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
6. A comparative evaluation of prasugrel and clopidogrel in patients with acute coronary syndrome undergoing percutaneous coronary intervention.
Dasbiswas A; Rao MS; Babu PR; Vijayvergiya R; Nayak R; Dani S; Tyagi S; Hiremath S; Patel T; Alexander T; Prakash VS; Singh DP; Yadav MK; Pathak K; Srivastava A
J Assoc Physicians India; 2013 Feb; 61(2):114-6, 126. PubMed ID: 24471250
[TBL] [Abstract][Full Text] [Related]
7. Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolysis In Myocardial Infarction) analysis.
Antman EM; Wiviott SD; Murphy SA; Voitk J; Hasin Y; Widimsky P; Chandna H; Macias W; McCabe CH; Braunwald E
J Am Coll Cardiol; 2008 May; 51(21):2028-33. PubMed ID: 18498956
[TBL] [Abstract][Full Text] [Related]
8. Dual thienopyridine low-response to clopidogrel and prasugrel in a patient with STEMI, cardiogenic shock and early stent thrombosis is overcome by ticagrelor.
Orban M; Riegger J; Joner M; Tada T; Okrojek R; Hausleiter J; Kastrati A; Massberg S; Sibbing D
Platelets; 2012; 23(5):395-8. PubMed ID: 22671583
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of prasugrel compared with clopidogrel in patients with acute coronary syndromes: design and rationale for the TRial to assess Improvement in Therapeutic Outcomes by optimizing platelet InhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38).
Wiviott SD; Antman EM; Gibson CM; Montalescot G; Riesmeyer J; Weerakkody G; Winters KJ; Warmke JW; McCabe CH; Braunwald E;
Am Heart J; 2006 Oct; 152(4):627-35. PubMed ID: 16996826
[TBL] [Abstract][Full Text] [Related]
10. New anti-platelet agents: the end of resistance?
Kastrati A
Thromb Res; 2012 Oct; 130 Suppl 1():S53-5. PubMed ID: 23026663
[TBL] [Abstract][Full Text] [Related]
11. Platelet inhibition by abciximab bolus-only administration and oral ADP receptor antagonist loading in acute coronary syndrome patients: the blocking and bridging strategy.
Christ G; Hafner T; Siller-Matula JM; Francesconi M; Grohs K; Wilhelm E; Podczeck-Schweighofer A
Thromb Res; 2013 Jul; 132(1):e36-41. PubMed ID: 23791395
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of enhanced inhibition of P2Y12-mediated platelet aggregation in patients with ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention.
Capranzano P; Mehran R; Tamburino C; Stone GW; Dangas G
Hosp Pract (1995); 2010 Nov; 38(4):38-43. PubMed ID: 21068525
[TBL] [Abstract][Full Text] [Related]
13. Platelet inhibition with prasugrel (CS-747) compared with clopidogrel in patients undergoing coronary stenting: the subset from the JUMBO study.
Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR
Postgrad Med J; 2006 Jun; 82(968):404-10. PubMed ID: 16754711
[TBL] [Abstract][Full Text] [Related]
14. Prasugrel is effective and safe for neurointerventional procedures.
Stetler WR; Chaudhary N; Thompson BG; Gemmete JJ; Maher CO; Pandey AS
J Neurointerv Surg; 2013 Jul; 5(4):332-6. PubMed ID: 22619468
[TBL] [Abstract][Full Text] [Related]
15. Clopidogrel resistance in diabetic patient with acute myocardial infarction due to stent thrombosis.
Samoš M; Šimonová R; Kovář F; Duraj L; Fedorová J; Galajda P; Staško J; Fedor M; Kubisz P; Mokáň M
Am J Emerg Med; 2014 May; 32(5):461-5. PubMed ID: 24560391
[TBL] [Abstract][Full Text] [Related]
16. Residual platelet reactivity, bleedings, and adherence to treatment in patients having coronary stent implantation treated with prasugrel.
Parodi G; Bellandi B; Venditti F; Carrabba N; Valenti R; Migliorini A; Grassellini S; Ramazzotti E; Antoniucci D
Am J Cardiol; 2012 Jan; 109(2):214-8. PubMed ID: 21996146
[TBL] [Abstract][Full Text] [Related]
17. Use of thromboelastography to tailor dual-antiplatelet therapy in patients undergoing treatment of intracranial aneurysms with the Pipeline embolization device.
McTaggart RA; Choudhri OA; Marcellus ML; Brennan T; Steinberg GK; Dodd RL; Do HM; Marks MP
J Neurointerv Surg; 2015 Jun; 7(6):425-30. PubMed ID: 24739599
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and safety of prasugrel with and without a glycoprotein IIb/IIIa inhibitor in patients with acute coronary syndromes undergoing percutaneous intervention: a TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel-Thrombolysis In Myocardial Infarction 38) analysis.
O'Donoghue M; Antman EM; Braunwald E; Murphy SA; Steg PG; Finkelstein A; Penny WF; Fridrich V; McCabe CH; Sabatine MS; Wiviott SD
J Am Coll Cardiol; 2009 Aug; 54(8):678-85. PubMed ID: 19679245
[TBL] [Abstract][Full Text] [Related]
19. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
[TBL] [Abstract][Full Text] [Related]
20. Prasugrel for the treatment of coronary thrombosis: a review of pharmacological properties, indications for use and future development.
Tomasello SD; Tello-Montoliu A; Angiolillo DJ
Expert Opin Investig Drugs; 2011 Jan; 20(1):119-33. PubMed ID: 21143003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
